GW Pharma scuttles UK listing to trade on U.S. market

420Patients.com is accepting qualified medical marijuana patients and caregivers to join our network. We value every registered member and we hope to serve you in Arizona. This article brought to you by 420 community friends mmjbusinessdaily.com

GW Pharmaceuticals, a high-flying biotech firm in the United Kingdom that is seeking U.S. regulatory approval for a CBD-based drug, has abandoned its U.K. stock market listing to instead trade exclusively in the United States.

The firm announced it would ditch its Aim market listing this December, according to Britain’s Telegraph newspaper.

A company executive said it no longer needed a dual listing because the majority of its shares are now traded on the Nasdaq and held by U.S. investors.

GW Pharma is developing Epidiolex, a cannabis-based epilepsy drug for children. If approved by the U.S. Food and

GW Pharma scuttles UK listing to trade on U.S. market is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs

Leave a Reply

Skip to toolbar